Safety and Efficacy of Co-Trimoxazole for Treatment and Prevention of Plasmodium falciparum Malaria: A Systematic Review

Christine Manyando¹*, Eric M. Njunju², Umberto D’Alessandro²,³, Jean-Pierre Van geertruyden⁴

¹ Department of Public Health, Tropical Diseases Research Centre, Ndola, Zambia, ² Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium, ³ Medical Research Council Unit, Fajara, The Gambia, ⁴ International Health, University of Antwerp, Belgium, ⁵ Department of Biomedical Sciences, Tropical Diseases Research Centre, Ndola, Zambia

Abstract

Introduction: Cotrimoxazole (CTX) has been used for half a century. It is inexpensive hence the reason for its almost universal availability and wide clinical spectrum of use. In the last decade, CTX was used for prophylaxis of opportunistic infections in HIV infected people. It also had an impact on the malaria risk in this specific group.

Objective: We performed a systematic review to explore the efficacy and safety of CTX used for P.falciparum malaria treatment and prophylaxis.

Result: CTX is safe and efficacious against malaria. Up to 75% of the safety concerns relate to skin reactions and this increases in HIV/AIDS patients. In different study areas, in HIV negative individuals, CTX used as malaria treatment cleared 56%–97% of the malaria infections, reduced fever and improved anaemia. CTX prophylaxis reduces the incidence of clinical malaria in HIV-1 infected individuals from 46%–97%. In HIV negative non pregnant participants, CTX prophylaxis had 39.5%–99.5% protective efficacy against clinical malaria. The lowest figures were observed in zones of high sulfadoxine-pyrimethamine resistance. There were no data reported on CTX prophylaxis in HIV negative pregnant women.

Conclusion: CTX is safe and still efficacious for the treatment of P.falciparum malaria in non-pregnant adults and children irrespective of HIV status and antifolate resistance profiles. There is need to explore its effect in pregnant women, irrespective of HIV status. CTX prophylaxis in HIV infected individuals protects against malaria and CTX may have a role for malaria prophylaxis in specific HIV negative target groups.

Introduction

Worldwide, malaria is one of the most important causes of morbidity and mortality, with children under five years of age and pregnant women being the most severely affected groups. [1] An estimated 3.3 billion people were at risk of malaria in 2010. [2] Of all geographical regions, populations living in sub-Saharan Africa (SSA) have the highest risk of acquiring malaria; in 2010, 91% and 91% of malaria cases and deaths occurred in the World Health Organisation (WHO) African Region [1]. Artemisinin-based combination therapy (ACT) is currently the mainstay of malaria treatment in both children and adults, while in pregnancy it can be used only in the second and third trimester. [3] Pregnant women are more susceptible to malaria infection than other adults, resulting in placental malaria and anaemia and increasing the risk of low birth weight and infant mortality. [4–8] Approximately 50 million women living in malaria-endemic areas become pregnant each year, half of them in areas of SSA with stable malaria transmission. The strategies to control malaria during pregnancy rely on case management as well as on a package of preventive measures including insecticide treated nets (ITNs) and intermittent preventive treatment (IPTp) with sulfadoxine-pyrimethamine (SP), a folate inhibitor [9] and as per recommendation of WHO [10]. Malaria prevention is also important for children because of their increased susceptibility to severe illness and death. WHO recommends IPT with SP in infants [IPTi] within the context of the expanded programme of immunisation (EPI) as well as seasonal malaria chemoprevention, previously known as IPT in children [IPTc], with amodiaquine and SP given at regular intervals. This is in addition to the overall recommendations for malaria control that include ITNs, Insecticide Residual Spraying (IRS) and access to prompt diagnosis and treatment for malaria patients. SP is currently the only antimalarial drug used for IPTi or IPTp. However, SP efficacy for treatment of symptomatic malaria has declined over the years, raising concerns about its longevity for IPT [11].

Citation: Manyando C, Njunju EM, D’Alessandro U, Van geertruyden J-P (2013) Safety and Efficacy of Co-Trimoxazole for Treatment and Prevention of Plasmodium falciparum Malaria: A Systematic Review. PLoS ONE 8(2): e56916. doi:10.1371/journal.pone.0056916

Editor: Philip Bejon, Kenya Medical Research Institute (KEMRI), Kenya

Received November 10, 2012; Accepted January 15, 2013; Published February 22, 2013

Copyright: © 2013 Manyando et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Belgian Development Co-operation funded the process through an institutional collaboration between the Tropical Disease Research Center, Ndola, Zambia, and the Institute of Tropical Medicine, Antwerp, Belgium. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: cmanyando@yahoo.com
HIV infection, through immune suppression, affects the acquisition and persistence of immune response to malaria. [12] In SSA, HIV infection may cause an average increase of 1.3% in malaria prevalence and of 4.9% in malaria-related mortality [13]. Each year an extra three million clinical malaria cases and 65,000 malaria-related deaths can be attributed to HIV infection. [13] Among HIV infected pregnant women malaria infection [4,14–17] and clinical malaria [18,19] are more frequent with the latter giving rise to higher parasite densities than those in HIV-uninfected pregnant women. The proportion of placental malaria cases attributable to HIV co-infection increases with the number of pregnancies: 21-3% during the first pregnancy, 41-2% in second pregnancy and 50-2% in third or more pregnancies [20]. Further, immunological data indicate that HIV impairs parity-related specific immunity. [5] Cotrimoxazole (CTX) prophylaxis is currently recommended by WHO to prevent opportunistic infections in persons living with HIV/AIDS. [21] In HIV infected children, who are even more vulnerable, daily CTX prophylaxis is also recommended to prevent HIV-related opportunistic infections [22–25].

CTX is a drug combination consisting of trimethoprim and sulfamethoxazole. Trimethoprim (2,4-diamino-5-(3,4,5 tri-methoxybenzyl)pyrimidine) belongs to a group of compounds with antibacterial and antimalarial activity. It is an inhibitor of dihydrofolate reductase and has been shown to act as a sulfonamide potentiator. [26] The inhibitory action of the combination on bacterial metabolism and in treating bacterial diseases has been well documented. [26,27] Burroughs Wellcome and Company introduced trimethoprim and sulfamethoxazole (5-methyl-3-sulfanilamidoisoxazole) in the ratio 1:5. In dealing with bacterial infections, the dosage producing satisfactory treatment contained 320 mg of trimethoprim plus 1.6 g of sulfamethoxazole daily in divided doses for about seven days in adults. [20] A 1:5 combination of trimethoprim (8 mg/kg bodyweight) and sulfamethoxazole (40 mg/kg bodyweight) was found to effectively treat malaria infections in semi-immune individuals.

Figure 1. Prisma Flow Chart.
doi:10.1371/journal.pone.0056916.g001
Nigerian children aged 5–12 years. [29] It was also effective in treating chloroquine-resistant *P. falciparum* infections. [29] CTX is not gametocytocidal and its sporontocidal activity is unknown. Therefore, Wilkinson and colleagues suggested in 1973, to supplement CTX treatment with an effective gametocytocidal or sporontocidal drug in order to interrupt transmission. [30] More recently, several studies have confirmed higher gametocyte carriage after SP compared to other antimalarial drugs, with peak gametocyte prevalence at around seven days post-treatment. [31–35] However, gametocytes present in the peripheral blood after SP treatment seem to have low infectivity for *Anopheles gambiae sensu stricto* (ss) mosquitoes [36]. A similar increase of gametocyte carriage after CTX treatment has been observed. [37] CTX has similar mechanisms of action and resistance patterns to SP and therefore, concerns were raised on the potential impact of CTX resistance on SP efficacy, preventing the implementation of CTX prophylaxis in SSA [38,39].

CTX is well known as an antibacterial drug but less as an antimalarial. Nevertheless, considering the reports on the impact of CTX on malaria, both in HIV-infected and uninfected individuals, we reviewed the available evidence on safety and efficacy of CTX as an antimalarial for both preventive and curative use.

**Methods**

**Study Selection**

This systematic review follows PRISMA guidelines. We included all electronically available, peer reviewed articles. We included studies in English as well as abstracts for which a full study was not available such as conference deliberations as long as sufficient data for inclusion were provided. All eligible studies irrespective of sample size were included (see attached flow chart). A protocol for systematic reviews was not used to for this particular review.

**Study Participants**

The studies included comprise sample populations who were administered CTX for treatment or prophylaxis or any other drug administered to compare efficacy and safety with that of CTX. The review also includes data from in-vitro studies that involve CTX. The patients involved include children, adults and pregnant women, HIV/AIDS infected and uninfected individuals.

**Search Methods**

A literature search was performed to identify publications reporting on safety and efficacy of Cotrimoxazole for malaria treatment or prophylaxis. The search terms included: "Cotrimoxazole prophylaxis and malaria", "Cotrimoxazole malaria treatment", "Cotrimoxazole malaria and HIV", "Cotrimoxazole malaria drug resistance", "Cotrimoxazole, malaria in pregnancy", "trimethoprim-sulfamethoxazole and malaria prophylaxis", "trimethoprim-sulfamethoxazole and sulfadoxine-pyrimethamine". The search covered the period from 1962 to June 2012. The PubMed was last accessed on June 6th, 2012. The same terms were used to search other databases such as the ClinicalTrials.gov and the WHO International Clinical trials Registry Platform (ICTRP). The articles identified were downloaded and reviewed. Studies included were prospective and most of them were done in West Africa, East Africa and a few in Southern Africa. Articles selected were stratified according to the target group (children, non pregnant and pregnant adults) and HIV infected population.

**Results**

**Cotrimoxazole for Treatment of Malaria**

Several clinical trials reported that CTX was efficacious against *P. falciparum* malaria, both in children and adults and was generally safe as no adverse effects were reported from the studies reviewed (Table 1). In the 70 s and 80 s, CTX was reported to be as effective as chloroquine for treatment of malaria. Parasite clearance rates were similar but fever clearance rates were higher in the chloroquine group due to its antipyretic properties. No recrudescence was observed up to 60 days post-treatment. [30,40] However, CTX had no gametocytocidal effect. [29] In Tanzania, in the mid 90s, CTX cleared 97% of infections by day seven, while chloroquine only cleared 19%. [41] In 1991 and 1998, both in The Gambia and Uganda, CTX and SP were both effective in reducing fever, clearing parasitaemia and avoiding anaemia in children less than five years of age with uncomplicated malaria [42], although in Uganda efficacy varied by geographical areas. [43] In 1999, in a hyper-endemic area in Southwest Nigeria, both SP and CTX had similar efficacy; and the gametocyte prevalence and parasite density were high for both SP and CTX, though for the latter it was lower than for SP. [44] Later, from 2001 to 2005, in Kenya, Malawi and Nigeria several studies demonstrated that CTX was still efficacious (up to and above 90%) as antimalarial treatment in areas of high endemicity. [37,44–46]. These results reveal that CTX compares with standard treatment of SP for example in the two Kenyan endemic areas of Oyugi in the West and Tiwi in the coast in that their clinical and parasitological failure rates were similar. The combined incidence of parasitological failure over 14 days for the combined sites for CTX was 11% and SP was 16% (RR:0.72, p = 0.29). The 14 day clinical failure rate for the combined sites for CTX was 3.3% and for SP 5.5% (RR:1.69, p = 0.13) [45]. In Malawi in 2001, in the outskirts of Blantyre, an area of high malaria transmission, children were treated for malaria and pneumonia (using Integrated Management of Childhood Illness - IMCI) dual classification). Their clinical, parasitological responses as well as gametocyte prevalence were obtained. The results revealed a total of 78.2% of children receiving CTX and 80.0% receiving SP plus Erythromycin reached adequate clinical and parasitological responses (ACPRs) (p = 0.19) [37]. In a hyper-endemic area of south-western Nigeria, there was 11% treatment failure after 14 days of follow up of uncomplicated *P. falciparum* malaria for CTX which was used for treatment of malaria as was chloroquine, mefloquine, and SP. Independent predictors of failure were age <3 years (adjOR = 0.10; p = 0.007) and body temperature ≥38°C 2 days after the commencement of treatment (adjOR = 4.9; p = 0.03 [46].

**Cotrimoxazole Malaria Prophylaxis in Non Pregnant HIV Positive Population**

Cotrimoxazole prophylaxis is a well established strategy to prevent opportunistic infections in HIV-infected individuals [47–49]. Starting Highly Active Anti-Retroviral Therapy (HAART) should not be a reason for not starting or interrupting CTX prophylaxis as this was demonstrated to be beneficial when maintained for more than a year after HAART commencement. [50]. The rationale is that patients with CD4 cell counts >200 cells/µL are still at higher risk of opportunistic infections [51–55]. At present, the threshold of CD4 cell counts above which CTX is not advantageous has not yet been identified. [55] However, in the DART trial, carried out in a region where the efficacy of CTX
### Table 1. Summary of prospective studies assessing Cotrimoxazole used for malaria treatment.

| Country (author) | Year | Study population | Type of study | Sample size | Outcome: Efficacy/Safety | Comments |
|------------------|------|------------------|---------------|-------------|--------------------------|----------|
| Nigeria (Fasan O et al)[29] | 1970 | 5–12 years, school children with asymptomatic parasitaemia | RCT, single dose administered to all children as: (8 mg T & 40 mg SX); (4 mg T & 20 mg SX); 15 mg CQ/kg body wt against a placebo. FU up to 14 days | 200 | CTX in single dose is efficacious (cleared 100% parasitaemia in less than 72 hrs) against asymptomatic malaria infection and is safe (no adverse reactions reported) |
| Thailand (Wilkinson et al)[30] | 1972 | Adults, UM with pre-treatment gametocytaemia | Non-randomized trial, CTX treatment administered 12 hourly for 7 days. (FU duration not mentioned) | 12 | CTX cleared 100% asexual P. falciparum parasites (no adverse effects reported) |
| RSA (Hansford et al)[40] | 1978 | all ages except pregnant women, UM | RCT, CTX versus CQ. FU on days 7, 12, 42 and 60 | 63 (19 on std CTX, 23 on high dose CTX, and 21 on CQ) | CTX cleared 100% parasitaemia in less than 3 days; CTX high dose (4 tablets twice daily) for 2 days cleared 100% parasitaemia in 2-5 days. Efficacy comparable to chloroquine, pyrexia responded slower for CTX. But no recrudescence in 60 days (no adverse effects reported) |
| Gambia (Daramola et al)[42] | 1991 | 2 groups were studied; Group (1). 7 months to 23 months, UM and ARI; Group (2). 1 to 5-7 years, asymptomatic parasitaemia. | Non-randomized trial, CTX std treatment. FU on days 3, 6 and 21. | Group (1) 10 & Group (2) 65 | 0% parasitaemia on days 3, 6 and 21 except 1 patient who was positive on day 3 but reduced parasitaemia and negative on Day 21. 3-3% asymptomatic subjects were positive but markedly reduced parasites after 6 days. (no adverse effects reported) |
| Tanzania (Mutabingwa et al)[41] | 1996 | <5 years, UM, P. falciparum monoinfection | RCT, CTX versus CQ (25 mg base/kg over 3 days); FU days 14, 21 and 28. | 61 CTX vs 63 CQ | CTX cleared 97% within 7 days compared to CQ which cleared 19%. (no adverse effects reported) |
| Uganda (Kilian AHD et al)[43] | 1996 | <5 years, UM, P. falciparum monoinfection | Non-randomized trial CTX, with follow-up on days 3, 7 and 14 | 3 geographical areas: A1:66; A2:43 A3:50 | Effectiveness of 40/8 mg/kg CTX differed significantly according to geographical area by parasitological failure rates (43-9%, 34-9% and 10-0% for areas A1, A2. And A3, respectively). (no adverse effects reported) |
| Kenya (Omar et al)[45] | 1998 | <5 years, UM, P. falciparum monoinfection | RCT: CTX vs SP (one dose). FU on days 0, 1, 2, 3, and 4. | A1K. CTX 66 and SP 76; A2K CTX 57 and SP 69 | CTX and SP were both >90% efficacious with similar fever clearance time (FCT), Parasite clearance time (PCT) and haematological findings.(no adverse effects reported) |

Holo-endemic malaria areas in Kenya, CTX use could help to prevent the development of anti-folate resistance strains.
prophylaxis was most questioned, co-administering CTX with HAART halved mortality within the 72-week follow up. The effect in Uganda was sustained beyond 72 weeks, consistent with the reports that CTX is an effective agent for malaria prophylaxis in semi-immune adults [55].

CTX prophylaxis administered to non-pregnant, HIV-infected patients living in an area of moderate, stable malaria transmission reduced the risk of malaria infection (Table 2). In Uganda, 128 HIV-infected adults on HAART and CTX with sustained HIV viral load of ≤400 copies/µL for a period of 4 years had a low risk of malaria infection. [56] In another Ugandan prospective cohort study carried out on HIV infected adults living in a high malaria transmission area, CTX was associated with a 76% lower malaria incidence by 97%. [25] In another study, during a 6-month follow-up period, patients on CTX prophylaxis and HAART developed no clinical malaria as this finding was attributed to low parasite densities, as parasite densities correlate positively to occurrence of symptoms. [57] Other than long-term HAART, which restores immunity, long term use of CTX prophylaxis is perceived to contribute to the host’s response induced by HAART to achieve the asymptomatic P. falciparum parasitaemia. [57] Even when rates of antimicrobial resistance to CTX are high among diarrhoeal pathogens and other bacteria, CTX prophylaxis is still associated with reduction in mortality and reductions in malaria, diarrhoea, clinic visits and hospital admissions. [58] Apart from reducing HIV morbidity and mortality, an additional advantage of CTX and HAART is malaria prevention and the provision of ITNs reduces the incidence of malaria even further [25].

HIV exposed children experience increased morbidity and mortality in their first years of life compared with HIV uninfected children born to uninfected mothers. [59] Also in HIV-infected children, CTX prophylaxis and ITN use reduced malaria incidence dramatically in a highly endemic and highly resistant antifolate drug malaria setting. [25] It is important to note that the use of ITNs alone is associated with a 43% reduction in the incidence of malaria. [25,60,61] In Uganda, despite high rates of antimicrobial resistance to CTX among diarrhoeal pathogens and other bacteria, CTX prophylaxis was associated with 46% reduction in mortality and lower rates of malaria, diarrhoea, and hospital admissions. Adverse reactions were rare and affected only <2% per person-year and these were mainly muco-cutaneous in nature which resolved with therapy withdrawal. Restarting CTX prophylaxis in 89% of affected individuals, none had any further adverse reactions. [62] The rates of morbidity and mortality reduction in Uganda are similar to those found in other studies in Africa. [63–67] In randomized trials done in Uganda and Zimbabwe from 2003 to 2004, CTX prophylaxis significantly reduced mortality and malaria incidence in a sustained manner. [55] Further, another study in Uganda revealed that CTX prophylaxis taken by HIV infected individuals was associated with decreased morbidity and mortality among HIV negative family members [68].

### Table 1. Cotrimoxazole Malaria Prophylaxis in Non Pregnant HIV Negative Population

| Country (author) | Year* | Study population | Type of study | Sample size | Outcome: Efficacy/Safety | Comments |
|------------------|-------|------------------|---------------|-------------|--------------------------|----------|
| Nigeria (Sowunmi A, et al) [46] | 1999 | 6 months to 5 years, UM, P. falciparum mono-infection, >2,000 asexual forms/µL | RCT; CTX vs SP | CTX = 53; SP = 49 | CTX was 89% and SP 88% efficacious after 14 days | Hyperendemic malaria |
| Nigeria (Sowunmi A, et al) [46] | 2003 | <13 years UM, P. falciparum mono-infection, >1000 asexual forms/µL no concomitant illness | RCT; CTX vs SP or CQ; FU on days 1–7 and 14 | Only 101 exposed to CTX reported | CTX had 89% efficacy by day 14. Of the 11% failures, predictors of failure were age <3 years and body temperature ≥38°C 2 days after treatment commencement. (no adverse effects reported) | Assessed in hyperendemic area of southwestern Nigeria |
| Malawi (Hamel et al) [71] | 2001 | 6 months to 5 years, UM and pneumonia with P. falciparum mono-infection, >2,000 asexual forms/µL | RCT with CTX vs SP+E for 5 days; FU 1–4 days and days 7 and 14 | CTX = 104; SP+E = 101 | ACPR: 87-2% in CTX; 80% in SP+E; ACR CTX 96-1% and SP+E 88% (p = 0.03); (no adverse effects reported) | The Blantyre District is an area of high P. falciparum malaria |

* = Year of study
P = Year of publication.

ACPR = Adequate Clinical and Parasitological Response, ACR = Adequate Clinical Response, ARI = Acute Respiratory Infection, A1. = Bundibugyo area, Uganda. A2. = Kabarole east area, Uganda. A3. = Kabarole west area, Uganda. A1K = Tiwi, Kenya. A2K = Oyugis, Kenya. CTX = Cotrimoxazole, CTX standard treatment = (2 tablets twice daily for 5 days), CQ = Chloroquine, E = Erythromycin, FU = Follow up, Kg = kilograms, mg = milligrams, MPCT = Mean Parasite Clearance Time, RCT = Randomized clinical trial, SP = sulfadoxine-pyrimethamine, std = standard, SX = sulfamethoxazole, T = Trimethoprim, UM = uncomplicated malaria, vs = versus.

doi:10.1371/journal.pone.0056916.t001
seem to occur. CTX was generally safe, as only one patient in the Mali cohort with previous history of Hepatitis A infection and equivocal evidence of past or recent infection with Hepatitis B virus developed acute hepatitis which resolved after withdrawal of CTX. [69] From August 2007 to April 2008, in Tororo, Uganda, an area of extremely high malaria transmission and antifolate resistance, the protective efficacy of daily CTX prophylaxis against malaria in children was 39%. Thus, CTX prophylaxis was moderately protective against malaria in HIV exposed infants when continued beyond the HIV exposure period despite the high prevalence of Plasmodium genotypes associated with antifolate resistance. In this particular study, no episodes of skin reactions,
allergic drug reactions or other unexpected adverse reactions were reported with CTX administration [70].

Cotrimoxazole Malaria Prophylaxis during Pregnancy

Numerous studies have demonstrated that HIV infection nearly doubles the risk of placental malaria. [16,20,71] Some trials suggest that monthly IPT-SP regimens in HIV infected pregnant women can decrease the risk of placental malaria to levels seen among HIV-uninfected women receiving 2-dose IPT. [72,73] In HIV infected pregnant women on daily CTX, SP-IPT is not indicated as it may be associated with overlapping toxicities. [74] Fortunately, CTX prophylaxis has shown to decrease the prevalence of placental malaria in HIV infected women as much as IPT-SP in HIV uninfected women (Table 4).

Table 3. Cotrimoxazole malaria prophylaxis in non pregnant HIV negative population.

| Country (Author) | Year* | Study population | Type of study | Sample size | Outcome: Efficacy/Safety | Comments |
|-----------------|-------|------------------|---------------|-------------|--------------------------|----------|
| Mali (Thera)[69] | 2000  | 5–15 years in an on-going cohort study of incidence of malaria were eligible for inclusion | RCT within Cohort study | 160 in CTX group & 80 in the SP group (control); FU periods 11–8 weeks in CTX group and 11–7 weeks in SP group. | From baseline the prophylactic efficacy of CTX against uncomplicated malaria was 99.5% (CI 95%: 96.8%–100%); p<0.001 and 97% efficacy against infection. | Seasonal malaria transmission but intense. Study was conducted in peak malaria season |
| Uganda (Sandison et al)[66] | 2007 to 2008 | 6 weeks –9 months, documented HIV uninfected status with mother HIV infected, current breast feeding | Non-blinded RCT: CTX prophylaxis from enrolment until cessation of breast feeding and confirmation of negative HIV status or uninfected children randomized to stop CTX prophylaxis immediately or continue until 2 years old. | 203 breastfeeding HIV exposed infants; 185 HIV negative randomized to stop or continue until 2 years. | CTX when continued beyond the period of HIV exposure = 3.33 cases/person year; When CTX was stopped = 0.87 cases/person year. CTX yielded 39% reduction in malaria incidence (IRR 0.61 (95% CI 0.46 to 0.81), p = 0.001) | Area of study has high prevalence of plasmodium genotypes associated with antifolate resistance. |

* = Year of study.

CTX = Cotrimoxazole, FU = Follow up, IRR = Incidence Rate Ratio, PLHIV = people living with HIV/AIDs, RCT = Randomized clinical trial, SP = sulfadoxine pyrimethamine.
doi:10.1371/journal.pone.0056916.t003

A Malawian study observed a superior efficacy of CTX with or without SP-IPT compared to SP-IPT alone in reducing prevalence of microscopic and PCR-detected malaria infections and anaemia in HIV-infected pregnant women. [75] When taken in the first trimester, CTX intake in pregnancy has been associated with increased risk of folate deficiency, maternal anaemia and poor birth outcomes [76–79] and neural birth defects [80–82]. However, in the same Malawian study, CTX, with or without SP-IPT, was associated with reduced prevalence of maternal anaemia and higher haemoglobin concentration, consistent with beneficial effects in birth outcomes as previously reported in a Zambian study. [83] This further underscores the fact that for this target group, CTX prophylaxis may be beneficial. Therefore, Newman et al concluded that daily CTX can decrease the risk of placental malaria in HIV infected women [84].

Table 4. Cotrimoxazole for malaria prophylaxis during pregnancy in HIV positive population.

| Country (Author) | Year* | Study population | Type of study | Sample size | Outcome: Efficacy/Safety | Comments |
|-----------------|-------|------------------|---------------|-------------|--------------------------|----------|
| Malawi (Kapito-Tembo)[72] | 2005 to 2009 | 15 years, Gestation ≥34 weeks attending routine antenatal services | Cross sectional study | 1121 had data on CTX and/or SP-IPT intake | CTX+SP-IPT: microscopic malaria 0-6%, PCR: 3-6%; CTX only: microscopic malaria 2.7%, PCR 5.5% SI only: microscopic malaria 7.7%, PCR 13.5% | High malaria transmission area |
| Uganda (Newman)[84] | 2008 to 2009 (HIV infected) 2008 (HIV un-infected) | 23 to 33 years old PLHIV women at delivery, 19 to 29 years old HIV-uninfected women at delivery | Cross sectional study comparing placental malaria prevalence between HIV-infected women prescribed CTX and HIV-uninfected women prescribed IPT SP | 150 HIV-infected women on CTX; 336 HIV-uninfected women on SP-IPT | HIV+ CTX: 19% placental malaria smear, PCR positive 6%; HIV- SP-IPT: 26% placental malaria, PCR positive 9% | High malaria transmission area |

* = Year of study (if not available P = Year of publication).

CTX = Cotrimoxazole, HIV = Human Immunodeficiency virus, PCR = Polymerase Chain Reaction, PLHIV = people living with HIV/AIDS, SP-IPT = sulfadoxine-pyrimethamine-Intermittent Preventive Treatment.
doi:10.1371/journal.pone.0056916.t004
**Table 5. *P. falciparum* malaria – CTX resistance or CTX resistance versus SP resistance.**

| Country (Author) | Year* | Study population | Type of study | Sample size | Outcome: Efficacy/Safety | Comments |
|------------------|-------|------------------|---------------|-------------|--------------------------|----------|
| Liberia (Petersen 1987) | 1987 | *Plasmodium falciparum* isolates were tested against sulfadoxine, sulfamethoxazole, pyrimethamine and trimethoprim | In vitro susceptibility testing | Two isolates F32 (from Tanzania and sensitive to chloroquine and pyrimethamine) & K1 (from Thailand and resistant to Chloroquine and pyrimethamine) | The difference in IC50 between F32 and K1 against trimethoprim and CTX was much less than the difference between the IC50 values against pyrimethamine and SP. | Cross resistance between pyrimethamine and trimethoprim exists but is not complete. |
| Uganda (Malamba 2010) | 2001 | 3 to 34.5 years HIV infected adults and children | Prospective cohort study administering CTX prophylaxis | 3,601 blood smears (2,154 taking taking CTX prophylaxis and 1,447 not taking CTX | HIV infected taking CTX: dhfr triple mutant: 74% dhps mutant: 95% dhfr/dhps quintuple mutant 6.7% HIV infected not on CTX dhfr triple mutant: 70% (p = 0.71) dhps mutant: 88% (p = 0.21) dhfr/dhps quintuple mutant: 64% (p = 0.38). | Extremely high malaria transmission area. |
| Uganda (Malamba et al) | 2001 and 2002 | ≥5 years and <5 years, HIV uninfected household members of PLHIV taking or not taking CTX. | Prospective cohort study | 1,319 HIV-uninfected household members of PLHIV taking CTX; 1,248 HIV uninfected household members of PLHIV not taking CTX. | Proportion of malaria episodes caused by SP-resistant parasites; HIV-uninfected households not taking CTX. (Overall incidence of malaria [IRR = 0.67, 95% CI = 0.49–0.92]) | No evidence that CTX prophylaxis lead to the spread of SP resistant malaria parasites among household members not taking the drug. |
| Kenya (Hamel et al) | 2002 to 2003 | ≥15 years, not severely ill, not taking daily antibiotics for treatment of a chronic illness (excluding tuberculosis) | Prospective study to assess whether the use of daily CTX resulted in significant changes in antifolate and CTX resistance among common organisms | 3 study arms: 132 HIV negative 336 HIV-positive with CD4≥350µL received daily vitamins 692 HIV-positive with CD4<350 received daily CTX; median FU 24 weeks | Daily CTX did not result in increased *P.falciparum* antifolate resistance; reduced malaria incidence by 89–90%. Contributed to increased pneumococcus and commensal E. coli resistance (in lower CD4 subjects P<0.005) | There is need for surveillance with regard to CTX resistance among respiratory and diarrheal disease pathogens |
| Uganda (Gasasira et al) | 2004 to 2005 & 2005 to 2006 | HIV-infected children 1–10 years and healthy children 1–11 years; 2 prospective cohort studies: ITN +CTX and ITN | 292 HIV-infected children; Duration of FU: 0 to 2-4 years 517 uninfected children; Duration of FU = 0-2 to 2-4 years HIV uninfected | CTX gave 80% protective efficacy and this did not vary over 3 consecutive (9-5 month) periods; Prevalence of dhfr 164L mutation was higher in parasites from HIV-infected compared to HIV uninfected children (8% vs 1%, p = 0.001) | Study conducted in an area of widespread antifolate resistance. |

* = Year of study.

CTX = Cotrimoxazole, DHFR = Dihydrofolate reductase, DHPS = Dihydropteroate synthetase, E. coli = Escherichia coli, FUI = Follow up, HIV = Human Immunodeficiency Virus, IRR = Incidence Rate Ratio, PLHIV = people living with HIV/AIDS, RCT = Randomized clinical trial, SP = sulfadoxine pyrimethamine.

doi:10.1371/journal.pone.0056916.t005

Most studies have demonstrated CTX not associated with hyperbilirubinemia when administered to mothers during pregnancy and breast feeding. No cases of kernicterus were reported in neonates after maternal ingestion of sulfonamides [74, 85, 86]. Further, the database on drugs and lactation revealed that neonates after maternal ingestion of sulfonamides [74, 85, 86]. Nevertheless, recent studies in Tororo and Kampala, Uganda, found no association between CTX use and increased prevalence of mutations conferring antifolate resistance in HIV infected children and adults taking daily CTX prophylaxis [94, 95] (Table 5).

In Uganda, CTX prophylaxis in HIV-infected individuals did not increase the occurrence of SP-resistant malaria episodes.
diarrhoea. Cholestatic jaundice had also been documented. Sulfamethoxazole is known to cause headache, depression and hallucinations. [102] Hypersensitivity reactions like neutropenia, Stevens-Johnson syndrome (SJS) and Sweet's syndrome occur more often in HIV/AIDS patients. [102] The reactions in this group have been related to their poor ability to handle nitroso-derivatives of sulfamethoxazole. [103,104] Generally, the wide use over time has proven CTX to be safe.

The fact that in pregnant women CTX prophylaxis showed a similar prevalence of placental malaria in HIV infected women as IPT-SP in HIV uninfected women suggests that daily CTX can similarly decrease the risk of placental malaria. In HIV-infected pregnant women, CTX use was associated with decreased malaria infection, maternal anaemia and increased haemoglobin concentration, a finding consistent with the beneficial effects on birth outcomes. Therefore, CTX may have similar beneficial effects in other groups though there is currently no data available on its use as a malaria preventive measure in HIV uninfected pregnant women or children. The studies reporting on CTX prophylaxis in HIV infected pregnant women were cross-sectional studies and there could be residual confounding from unmeasured factors. Further, participants were only enrolled in the third trimester of pregnancy [75] and at delivery [84] and therefore the overall impact of CTX on malaria infection and anaemia may be underestimated. Despite these limitations, these studies provide important data on the impact of CTX prophylaxis on the epidemiology and clinical implications of placental malaria among HIV-infected women.

A limitation of this review is that most information available comes from East and Western Africa. Almost all cited publications are published in English and relevant literature in other languages may have been overlooked. Nevertheless, this review identified the need of determining the benefits of using CTX in HIV-uninfected risk groups, such as children and pregnant women. The constraints related to the use of CTX may relate to the fact that it should be taken daily and issues related to its acceptability, safety, adherence and potential selection of resistant strains including antibiotic resistance.

Conclusions

CTX has been extensively used for half a century as an antibiotic worldwide and in malaria endemic areas. CTX antimalarial effect, although scientifically proven, has been ignored. Its long term use in HIV infected children and adults, has proved that CTX is still effective for malaria prevention and treatment. This has been confirmed in a few studies in non-HIV infected population, mostly secondary analyses of HIV studies. More information is required for pregnant women, irrespective of HIV infection for whom no information is available. There is need for more randomized controlled trials to evaluate further the efficacy of CTX as antimalarial, since most of the available data are derived from descriptive studies.

Research on CTX safety, adherence and acceptability is still necessary if its role for malaria treatment and prophylaxis in groups other than HIV-infected individuals is to be established.

Author Contributions

Conceived and designed the experiments: CM JPV. Performed the experiments: CM JPV. Analyzed the data: CM EN UDA JPV. Wrote the paper: CM EN UDA JPV.

References

1. WHO (2012) World Malaria Report.
2. WHO (2010) World Malaria report: Summary.
27. Darrell JH, Garrod LP, Waterworth PM (1968) Trimethoprim: laboratory and clinical studies. J Clin Pathol 21: 202–209.

28. Reeves DS, Fairies MC, Pursell RE, Brunffitt W (1969) Trimethoprim-sulphonamide therapy: comparative study in urinary infection in children. J Antimicrob Chemother 4: 541–549.

29. Faan PO (1971) Trimethoprim plus sulphonamide compared with chloroquin in the treatment and suppression of malaria in African schoolchildren. Ann Trop Med Parasit 65: 117–121.

30. Wilkinson RN, Colwell EJ, Nevesgatanond S (1973) Effect: of sulfonamide-trimethoprim on the viability of Plasmodium falciparum gametocytes. Trans R Soc Trop Med Hyg 67: 148–149.

31. von SL, Jawaara M, Coleman R, Doherty T, Walraven G, et al. (2001) Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimeth- amine/sulphadoxine, and pyrimethamine/sulfadoxine combined with artemesine in young Gambians with uncomplicated malaria. Trop Med Int Health 6: 92–98. tmi6835 [pii]

32. Schellenberg DB, Kagihuva E, Drakeley C, Malele A, Wigan J, et al. (2002) The safety and efficacy of pyrimethamine-sulphadoxine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 67: 17–23.

33. Chillo F, Mwase A, Chirwa L, Buragdo A, Arevalo-Herrera M, et al. (2002) Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. Am J Epidemiol 156: 230–238.

34. Robert V, Assovo-Amhene HP, Le Horan YJ, Troupe JF (2000) Gametocytauera: an antibody test for mosquitoes of patients with uncomplicated Plasmodium falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine. Am J Trop Med Hyg 62: 210–216.

35. Akin NI, Drakeley C, Kings T, Simon B, Sekouro K, et al. (2006) Dynamics of P. falciparum gametocyt density in symptomatic patients in an area of intense perennial transmission in Tanzania. Am J Trop Med Hyg 63: 199–201.

36. Kone A, Siehlieb-Stoter R, Van Gemert GJ, Dana A, Niangali H, et al. (2010) Sulfadoxine-pyrimethamine impairs Plasmodium falciparum gametocyte infectivity and Anopheles mosquitoes survival. Infect Genet Evol 10: 1221–1228. S1471-2126(10)00065-5 [pii];10.1016/j.meegid.2009.10.004 [doi].

37. Hamel MJ, Holtz T, Mikandala C, Kaimila N, Chizani N, et al. (2005) Efficacy of trimethoprim-sulfadiazine in the treatment of uncomplicated malaria in children with integrated management of childhood illness dual classifications of malaria and pneumonia. Am J Trop Med Hyg 73: 609–615. 73/3/609 [pii].

38. Gill CJ, Sahin LL, Tham J, Haner DH (2004) Reconsidering empirical cotrimoxazole prophylaxis for infants exposed to HIV infection. Bull World Health Organ 82: 290–297.

39. Lyen L, Jacobs J, Colebunders R (2007) Co-trimoxazole prophylaxis in tropical countries in the era of highly active antiretroviral therapy: do we know enough? Trans R Soc Trop Med Hyg 101: 1039–1060. S0035-9597(07)00207-6 [pii];10.1016/j.trstmh.2007.07.001 [doi].

40. Harford CF, Hoiland J (1982) An evaluation of co-trimoxazole in the treatment of Plasmodium falciparum malaria. S Afr Med J 61: 312–314.

41. Mutabingwa TK, Roum A, Byeghej J (1996) Chemotherapeutic efficacy of cotrimoxazole and sulfadiazine in the treatment of uncomplicated malaria in pregnant women in western Tanzania. Am J Trop Med Hyg 65: 623–630.

42. Schellenberg D, Kahigwa E, Drakeley C, Malende A, Wigayi J, et al. (2002) The effect of ivermectin plus co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated nets on the frequency of malaria in HIV-1-infected adults in Uganda: a randomised trial. Lancet Infect Dis 2: 103–114. S1473-3099(01)00400-4 [pii];10.1016/S1473-3099(01)00400-4 [doi].

43. Killian AH, Jelinek T, Prislin I, Kabagambe G, Byamukama W, et al. (1998) Contribution of co-trimoxazole prophylaxis, antiretroviral therapy and insecticide-treated nets to the reduction of Plasmodium falciparum malaria in maternal HIV and malaria infection on pregnancy and perinatal outcome in sub-Saharan Africa. Am J Trop Med Hyg 67: 195–203. 1984-0753-001/4.5 [pii];10.4269/ajtmh.2001.67.195 [doi].

44. Sowunmi A, Fateye BA, Adedeji AA, Fehintola FA, Bamgboye AE, et al. (2005) Efficacy of cotrimoxazole prophylaxis for prevention of malaria in HIV-infected children in a high transmission area in southwestern Nigeria. Malar J 7: 134. 1475-2875-7-134 [pii];10.1186/1475-2875-7-134 [doi].

45. Omar SA, Bakari A, Owiti A, Adagu IS, Warhurst DC (2001) Co-trimoxazole prophylaxis for P. falciparum malaria in HIV-infected children in western Kenya. J Infect Dis 184: 699–701. 1008-1899/10/0100699-01 [pii].

46. Akim NI, Drakeley C, Kingo T, Simon B, Sekouro K, et al. (2000) Dynamics of P. falciparum gametocyte density in symptomatic patients in an area of intense perennial transmission in Tanzania. Trans R Soc Trop Med Hyg 94: 385–398.

47. Daramola OO, Alonso PL, D’Olksey TJ, Twumasi P, McArdle TF, et al. (1991) Sensitivity of Plasmodium falciparum in The Gambia to co-trimoxazole. Trans R Soc Trop Med Hyg 85: 550–552.

48. Kilian AH, Jelinek T, Prislin I, Kabagambe G, Byamukama W, et al. (1998) Resistance in vivo to cotrimoxazole, sulfadiazine and pyrimethamine in patients with uncomplicated Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 92: 197–200.

49. Sovunmi A, Gholojo GO, Fayera BA, Adegedi AA (2006) Predictors of the failure of treatment with trimethoprim-sulfadoxine in children with uncomplicated Plasmodium falciparum malaria. Ann Trop Med Parasitol 100: 205–211. 10.1179/1368490609X917611365131 [pii].

50. Morrow J, Eykusu J, Leitch CA, Were W, Downing R, et al. (2006) Effect of cotrimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated beds on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 367: 1256–1261. S0140-6736(06)68541-3 [pii];10.1016/S0140-6736(06)68541-3 [doi].

51. Byakala-Kalubo P, Dhumbe E, Kamya M (2007) Effect of co-trimoxazole prophylaxis on malaria treatment outcome in Ugandan patients. Afr Health Sci 7: 86–92. 10.5555/ahs.2007.7.2.86 [pii].

52. Mermign J, Jukov J, Eykusu J, Leitch CA, Were W, Downing R, et al. (2006) Effect of cotrimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated beds on the frequency of malaria in HIV-1-infected adults in Uganda: A randomised controlled trial. Locatie. Cyst Infect Dis 34: 1254–1258. S0201-4838(10)00116-0 [pii];10.1016/j.ijpara.2010.05.004 [doi].

53. Corbett EL, Churchyard GJ, Charalambous S, Samba B, Moloi V, et al. (2002) Morbidity and mortality in South African gold miners: impact of untreated malaria due to human immunodeficiency virus. Clin Infect Dis 34: 1251–1258. S0213-2256(01)01435-3 [pii];10.1086/340114 [doi].

54. Gilks CF, Ojoo SA, Ojoo JC, Brindle RJ, Paul J, et al. (1996) Invasive pneumococcal disease in a cohort of predominantly HIV-1-infected female sex-workers in Nairobi, Kenya. Lancet 347: 718–723.
72. Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, et al. (1998) Efficacy of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 356: 1051–1056. S0140-6736(00)02277-6 [pii];10.1016/S0140-6736(00)02277-6 [doi].

Walker AS, Ford D, Gilks CF, Munderi P, Sasi F, et al. (2010) Daily cotrimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 375: 1278–1286. S0140-6736(10)60557-8 [pii];10.1016/S0140-6736(10)60557-8 [doi].

Nakanjako D, Kiragga AN, Castelnuovo B, Kyabayinze DJ, Kamya MR, et al. (2011) Low prevalence of Plasmodium falciparum antigenemia among asymptomatic HAART-treated adults in an urban cohort in Uganda. Malar J 10: 66. 1475-2875-10-66 [pii];10.1186/1475-2875-10-66 [doi].

Njama-Meya D, Kamya MR, Dorsey G (2004) Asymptomatic parasitaemia as a risk factor for symptomatic malaria in a cohort of Ugandan children. Trop Med Int Health 9: 862–866. 10.1111/j.1365-3156.2004.01277.x [pii];TMI1277 [pii].

Yoshimune H, Oishi K, Mubije H, Nahova H, Takahashi H, et al. (2001) Community-acquired pneumonia in Ugandan adults: short-term parenteral ampicillin therapy for bacterial pneumonia. Am J Trop Med Hyg 64: 172–177.

Neves AM, Correia J, Epipale J, Gomes N, Guillaume J. (2013) Mortality of infected and uninfected births born to HIV-infected mothers in Africa: a pooled analysis. Lancet 363: 1246–1249. S0140-6736(14)71407-7 [pii];10.1016/S0140-6736(14)71407-7 [doi].

see Nkia F, Tshipanji DJ, Kariuki SK, Phillips-Howard PA, Mikel LJ, et al. (2003) Impact of permethrin-treated bed nets on malaria, anemia, and growth in infants in an area of intense perennial malaria transmission in western Kenya. Am J Trop Med Hyg 68: 68–77.

see Kiale FG, Tshipanji DJ, Phillips-Howard PA, Haswky WA, Friedman JF, et al. (2005) Impact of permethrin-treated bed nets on malaria and all-cause morbidity in young children in an area of intense perennial malaria transmission in western Kenya: cross-sectional survey. Am J Trop Med Hyg 72: 100–107.

Mermin JL, Lule J, Ekwaru PM, Malamha S, Downing R, et al. (2004) Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4 cell count, and viral load in HIV infection in rural Uganda. Lancet 364: 1428–1434. S0140-6736(04)16725-5 [pii];10.1016/S0140-6736(04)16725-5 [doi].

Widmer JD, Raviglione MC, Darby SC, De Cock KM, Harries AD, et al. (2006) Reduction in pretreatment and delivery maternal mortality after the introduction of antenatal cotrimoxazole prophylaxis among HIV-infected women with low CD4 cell counts. J Infect Dis 194: 1510–1518. JID36726 [pii];10.1086/508896 [doi].

Nakamoto PM, Waniau H, Badri M, Arinaitwe E, Waldman S, et al. (2003) Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda. Malar J 5: 254. 1475-2875-2-254 [pii];10.1186/1475-2875-2-254 [doi].

Foraz F, McConnell M, Nakamoto PM, Homyo J, Brooks JT, et al. (2006) Systematic review of the safety of trimethoprim-sulfamethoxazole for prophylaxis in HIV-infected pregnant women: implications for resource-limited settings. AIDS Rev 8: 24–36.

Tarsolo P (2007) Lamc0296. TMJ1277 [pii].

Hernandez-Diaz S, Weir SK, Mitchell AA (2000) Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 343: 1608–1614. 10.1056/NEJM200011303432204 [pii];10.1016/S0140-6736(00)02727-6 [doi].

Peters PJ, Thielen MC, Parrie ME, Newman RD (2007) Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Saf 30: 481–501. 3063 [pii].

Capito-Tembo A, Mshonza SR, van Hensbroek MB, Phiri K, Fitzgerald M, et al. (2006) Prevalence of malaria parasitaemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine/pyrimethamine intermittent preventive therapy during pregnancy in Malawi. J Infect Dis 200: 464–472. jid072 [pii];10.1093/infdis/jid072 [doi].

Sungure-Riz AM, Savita DA, Zvezd SH, Thorp JM, Herrera A (2004) Second trimester folic acid supplementation for women at risk of preterm birth. Cochrane Database Syst Rev: CD001209.

Molyo AM, Kirke PN, Brody LC, Scott JM, Mills JL (2008) Effects of folic acid and vitamin B12 deficiencies during pregnancy on fetal, infant, and child development. Food Nutr Bull 29: S101–S111.

WHO (2008) Folate and vitamin B12 deficiencies: proceedings of a WHO technical consultation held 10–21 October, 2005, in Geneva, Switzerland. World Health Organization. Food Nutr Bull 29: S1–S13.

Heimpel H, Rahagazachar A (1987) Hematological side effects of cotrimoxazole. Int J Infect Dis 5: 248–253.
97. Hamel MJ, Greene C, Chiller T, Ouma P, Poljak C, et al. (2008) Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults? Am J Trop Med Hyg 79: 320–330. 79/3/320 [pii].
98. Petersen E (1987) In vitro susceptibility of Plasmodium falciparum malaria to pyrimethamine, sulfadoxine, trimethoprim and sulfamethoxazole, singly and in combination. Trans R Soc Trop Med Hyg 81: 238–241.
99. Feikin DR, Dowell SF, Nwanyamwe OC, Klugman KP, Kazembe PN, et al. (2000) Increased carriage of trimethoprim/sulfamethoxazole-resistant Streptococcus pneumoniae in Malawian children after treatment for malaria with sulfadoxine/pyrimethamine. J Infect Dis 181: 1501–1505. JID991074 [pii];10.1086/315382 [doi].
100. WHO (2010) WHO policy recommendation on IPTi.
101. Fehintola FA (2010) Cotrimoxazole, clinical uses and malaria chemotherapy. Afr J Med Med Sci 39: 63–68.
102. Petri WA (2012) Sulfamethoxazole; Trimethoprim sulfamethoxazole, Quinolone and agents for Urinary Tract Infection. In: Brunton LL, Lj, Parker KL, editors. Gilman and Goodman’s The Pharmacological Basis of Therapeutics. McGraw-Hill.
103. Farrel J, Naisbitt DJ, Drummond NS, Depta JP, Vilar FJ, et al. (2003) Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans. J Pharmacol Exp Ther 306: 229–237. 10.1124/jpet.103.050112 [doi];jpet.103.050112 [pii].
104. Joos B, Blaser J, Opravil M, Chave JP, Luthy R (1995) Monitoring of cotrimoxazole concentrations in serum during treatment of pneumocystis carinii pneumonia. Antimicrob Agents Chemother 39: 2661–2666.